アスピリン市場：製品、包装、剤形、投与量、流通チャネル、エンドユーザー別-2025年～2030年世界予測

アスピリン市場は、2023年に24億9,000万米ドルと評価され、2024年には25億8,000万米ドルに達すると予測され、CAGR 4.62%で成長し、2030年には34億2,000万米ドルに達すると予測されています。

アスピリンは、鎮痛、抗炎症、解熱作用で知られる広く使用されている医薬品で、世界的に市販薬と処方薬の定番となっています。その必要性は主に、疼痛管理、解熱、心血管イベントの予防といった効能に起因しており、現代医学におけるその地位を確固たるものにしています。この医薬品は、疼痛管理のための個人消費者、術後ケアのためのヘルスケア施設、関節炎や心血管保護などの慢性疾患のための長期的なヘルスケア管理など、多様なエンドユーザーにわたって応用されています。アスピリン市場の成長は、心血管疾患の有病率の増加、老人人口の増加、疼痛管理ソリューションに対する継続的な需要といった要因に大きく影響されています。さらに、アスピリンの予防ヘルスケア効果に対する消費者の意識の高まりも、その普及を後押ししています。しかし、胃腸合併症を含む長期使用に伴う重篤な副作用による制約があり、普及の妨げになる可能性があります。また、規制上の課題や代替療法の利用可能性も大きな課題となっています。緩衝化アスピリンのようなより安全な製剤の開発や、がん予防のような新たな治療領域におけるアスピリンの潜在的役割の探求にチャンスがあります。アスピリンの可能性を追求し、安全性プロファイルを改善するための研究開発への投資は、大きな競争優位性をもたらします。市場は多数のジェネリック医薬品プレーヤーとの競争が激しいため、イノベーションと的を絞ったマーケティング戦略による差別化が極めて重要です。市場関係者には、流通網を強化するための戦略的パートナーシップや提携に注力し、消費者に安全な使用法を啓蒙するキャンペーンに取り組むことが推奨されます。チュアブルや徐放性錠剤のような剤形や送達方法の革新は、潜在的な成長の道を示すものであり、また、アスピリンの広範な健康用途に関する継続的な調査により、新たな有利な市場が明らかになる可能性があります。

市場力学：急速に進化するアスピリン市場の主要市場インサイトを公開

アスピリン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心血管疾患の有病率の増加
  • がん予防および炎症性疾患の治療におけるアスピリンの応用拡大
  • 慢性疾患に罹患しやすい高齢化人口の増加
• 市場抑制要因
  • 有効性が向上し、副作用の少ない代替薬の入手可能性
• 市場機会
  • アスピリンの製剤改良のための研究開発投資
  • オンラインプラットフォームと遠隔医療の急成長
• 市場の課題
  • アスピリンの新しい製剤や用途の承認に対する厳しい規制要件

ポーターの5つの力：アスピリン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、アスピリン市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アスピリン市場における外部からの影響の把握

外部マクロ環境要因は、アスピリン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アスピリン市場における競合情勢の把握

アスピリン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアスピリン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アスピリン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アスピリン市場における成功への道筋を描く

アスピリン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の罹患率の増加
    • がん予防と炎症性疾患の治療におけるアスピリンの応用拡大
    • 慢性疾患にかかりやすい高齢化人口の増加
  • 抑制要因
    • 効果が向上し、副作用が少ない代替医療の利用可能性
  • 機会
    • アスピリンの強化処方のための研究開発への投資
    • オンラインプラットフォームと遠隔医療の急成長
  • 課題
    • アスピリンの新しい処方と用途の承認に関する厳格な規制要件
• 市場セグメンテーション分析
  • 製品：鎮痛作用と抗炎症作用により、定期的なアスピリンの利用が増加
  • エンドユーザー：アスピリンは幅広い利用が可能であるため、クリニック全体で利用が拡大しています。
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アスピリン市場：製品別

• バッファリングされたアスピリン
• 腸溶性コーティングアスピリン
• レギュラーアスピリン

第7章 アスピリン市場：包装別

• ブリスターパック
• ボトル
• サシェ

第8章 アスピリン市場：剤形別

• カプセル
• ジェル
• 粉末
• タブレット

第9章 アスピリン市場：投与量別

• 高用量
• 低用量
• 中用量

第10章 アスピリン市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 アスピリン市場：エンドユーザー別

• クリニック
• ホームケア
• 病院
• 製薬会社
• 調査機関

第12章 南北アメリカのアスピリン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋のアスピリン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのアスピリン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ビル＆メリンダ・ゲイツ財団が資金提供しているPEARLS試験では、世界各国の機関と協力し、AIツールを活用して、子癇前症を予防するための最適なアスピリン投与量を調査しています。
• 戦略分析と提言

企業一覧

• 1. Abbott Laboratories
• 2. Anhui Chemical Group Co., Ltd.
• 3. Bayer AG
• 4. Bristol-Myers Squibb Company
• 5. China Meheco Topfond Pharma Co., Ltd.
• 6. Cigna Corporation
• 7. Divi's Laboratories Limited
• 8. Dow Chemical Company
• 9. Dr. Reddy's Laboratories Ltd.
• 10. GlaxoSmithKline PLC
• 11. Globe Quimica S.A.
• 12. Granules India Limited
• 13. Hebei Jiheng (Group) Pharmaceutical Co., Ltd.
• 14. Hubei Biocause Heilen Pharmaceutical Co., Ltd.
• 15. Jiangsu Nanjing Huaxing Chemical Co., Ltd.
• 16. Jiangsu Pioneer Pharma Co., Ltd.
• 17. Lupin Pharmaceuticals, Inc.
• 18. Merck & Co., Inc.
• 19. Mylan N.V.
• 20. Nanjing Well Pharmaceutical Technology Co., Ltd.
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. SEQENS SAS
• 24. Shandong Xinhua Pharmaceutical Co., Ltd.
• 25. Sun Pharmaceutical Industries Ltd.
• 26. Taj Pharmaceuticals Ltd.
• 27. Zhenjiang Gaopeng Pharmaceutical Co., Ltd.

LIST OF FIGURES

• FIGURE 1. ASPIRIN MARKET RESEARCH PROCESS
• FIGURE 2. ASPIRIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ASPIRIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ASPIRIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ASPIRIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ASPIRIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ASPIRIN MARKET SIZE, BY PACKAGING, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ASPIRIN MARKET SIZE, BY PACKAGING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ASPIRIN MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ASPIRIN MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ASPIRIN MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ASPIRIN MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ASPIRIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ASPIRIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ASPIRIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ASPIRIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ASPIRIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ASPIRIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ASPIRIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ASPIRIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ASPIRIN MARKET DYNAMICS
• TABLE 7. GLOBAL ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ASPIRIN MARKET SIZE, BY BUFFERED ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ASPIRIN MARKET SIZE, BY ENTERIC-COATED ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ASPIRIN MARKET SIZE, BY REGULAR ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ASPIRIN MARKET SIZE, BY BLISTER PACKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ASPIRIN MARKET SIZE, BY BOTTLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ASPIRIN MARKET SIZE, BY SACHETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ASPIRIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ASPIRIN MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ASPIRIN MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ASPIRIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ASPIRIN MARKET SIZE, BY HIGH-DOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ASPIRIN MARKET SIZE, BY LOW-DOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ASPIRIN MARKET SIZE, BY MEDIUM-DOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ASPIRIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ASPIRIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ASPIRIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ASPIRIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ASPIRIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ASPIRIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ASPIRIN MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ASPIRIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ASPIRIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 53. CANADA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. CANADA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 55. CANADA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 56. CANADA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 57. CANADA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CANADA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES ASPIRIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC ASPIRIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 85. CHINA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. CHINA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 87. CHINA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 88. CHINA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 89. CHINA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. CHINA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 91. INDIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. INDIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 93. INDIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 94. INDIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 95. INDIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. INDIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA ASPIRIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 194. ITALY ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. ITALY ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 196. ITALY ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 197. ITALY ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 198. ITALY ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. ITALY ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 218. POLAND ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 219. POLAND ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 220. POLAND ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 221. POLAND ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 222. POLAND ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. POLAND ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 224. QATAR ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. QATAR ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 226. QATAR ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 227. QATAR ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 228. QATAR ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. QATAR ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM ASPIRIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM ASPIRIN MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM ASPIRIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM ASPIRIN MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM ASPIRIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM ASPIRIN MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 284. ASPIRIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 285. ASPIRIN MARKET, FPNV POSITIONING MATRIX, 2023

The Aspirin Market was valued at USD 2.49 billion in 2023, expected to reach USD 2.58 billion in 2024, and is projected to grow at a CAGR of 4.62%, to USD 3.42 billion by 2030.

Aspirin, a widely used pharmaceutical agent known for its analgesic, anti-inflammatory, and antipyretic properties, is a staple in both over-the-counter and prescription medications globally. Its necessity primarily stems from its efficacy in managing pain, reducing fever, and preventing cardiovascular events, which has cemented its place in modern medicine. This drug finds applications across a diverse range of end-users, including individual consumers for pain management, healthcare facilities for post-operative care, and long-term healthcare management for chronic conditions like arthritis and cardiovascular protection. The aspirin market's growth is heavily influenced by factors such as increasing prevalence of cardiovascular diseases, rising geriatric population, and the ongoing demand for pain management solutions. Additionally, growing consumer awareness about the preventive healthcare benefits of aspirin fuels its adoption. However, the market faces limitations due to the serious side effects associated with long-term use, including gastrointestinal complications, which may hinder widespread usage. Regulatory challenges and the availability of alternative therapies also pose significant challenges. Opportunities lie in the development of safer formulations, such as buffered aspirin, and the exploration of aspirin's potential role in emerging therapeutic areas like cancer prevention. Investment in R&D to explore aspirin's full potential and improve safety profiles can offer significant competitive advantages. As the market is highly competitive with numerous generic players, differentiation through innovation and targeted marketing strategies is crucial. Market players are recommended to focus on strategic partnerships and collaborations to enhance their distribution networks and engage in awareness campaigns to educate consumers about safe usage. Innovation in dosage forms and delivery methods, like chewables or sustained-release tablets, presents potential growth avenues, while ongoing research into aspirin's broader health applications could reveal new, lucrative markets.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aspirin Market

The Aspirin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cardiovascular diseases
  • Expanding applications of aspirin for cancer prevention and treatment of inflammatory conditions
  • Rise in aging population susceptible to chronic diseases
• Market Restraints
  • Availability of Alternative Medications with improved efficacy and fewer side effects
• Market Opportunities
  • Investment in R&D for enhanced formulations of aspirin
  • Burgeoning growth in online platforms and telemedicine
• Market Challenges
  • Stringent regulatory requirements for the approval of new formulations and applications of aspirin

Porter's Five Forces: A Strategic Tool for Navigating the Aspirin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aspirin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aspirin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aspirin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aspirin Market

A detailed market share analysis in the Aspirin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aspirin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aspirin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aspirin Market

A strategic analysis of the Aspirin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aspirin Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Anhui Chemical Group Co., Ltd., Bayer AG, Bristol-Myers Squibb Company, China Meheco Topfond Pharma Co., Ltd., Cigna Corporation, Divi's Laboratories Limited, Dow Chemical Company, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Globe Quimica S.A., Granules India Limited, Hebei Jiheng (Group) Pharmaceutical Co., Ltd., Hubei Biocause Heilen Pharmaceutical Co., Ltd., Jiangsu Nanjing Huaxing Chemical Co., Ltd., Jiangsu Pioneer Pharma Co., Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Nanjing Well Pharmaceutical Technology Co., Ltd., Pfizer Inc., Sanofi S.A., SEQENS SAS, Shandong Xinhua Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Ltd., and Zhenjiang Gaopeng Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Aspirin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Buffered Aspirin, Enteric-Coated Aspirin, and Regular Aspirin.
• Based on Packaging, market is studied across Blister Packs, Bottles, and Sachets.
• Based on Dosage Form, market is studied across Capsules, Gels, Powders, and Tablets.
• Based on Dosage, market is studied across High-Dose, Low-Dose, and Medium-Dose.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End Users, market is studied across Clinics, Home Care, Hospitals, Pharmaceutical Companies, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cardiovascular diseases
    • 5.1.1.2. Expanding applications of aspirin for cancer prevention and treatment of inflammatory conditions
    • 5.1.1.3. Rise in aging population susceptible to chronic diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of Alternative Medications with improved efficacy and fewer side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in R&D for enhanced formulations of aspirin
    • 5.1.3.2. Burgeoning growth in online platforms and telemedicine
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements for the approval of new formulations and applications of aspirin
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing utilization of regular aspirin owing to its pain-relieving and anti-inflammatory properties
  • 5.2.2. End Users: Evolving utilization of aspirin across the clinics owing to its broad availability
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Aspirin Market, by Product

• 6.1. Introduction
• 6.2. Buffered Aspirin
• 6.3. Enteric-Coated Aspirin
• 6.4. Regular Aspirin

7. Aspirin Market, by Packaging

• 7.1. Introduction
• 7.2. Blister Packs
• 7.3. Bottles
• 7.4. Sachets

8. Aspirin Market, by Dosage Form

• 8.1. Introduction
• 8.2. Capsules
• 8.3. Gels
• 8.4. Powders
• 8.5. Tablets

9. Aspirin Market, by Dosage

• 9.1. Introduction
• 9.2. High-Dose
• 9.3. Low-Dose
• 9.4. Medium-Dose

10. Aspirin Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Aspirin Market, by End Users

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Home Care
• 11.4. Hospitals
• 11.5. Pharmaceutical Companies
• 11.6. Research Institutes

12. Americas Aspirin Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Aspirin Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Aspirin Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. PEARLS trial, funded by Bill and Melinda Gates Foundation, explores optimal aspirin doses to prevent pre-eclampsia, collaborating with global institutions and utilizing AI tools
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Anhui Chemical Group Co., Ltd.
• 3. Bayer AG
• 4. Bristol-Myers Squibb Company
• 5. China Meheco Topfond Pharma Co., Ltd.
• 6. Cigna Corporation
• 7. Divi's Laboratories Limited
• 8. Dow Chemical Company
• 9. Dr. Reddy's Laboratories Ltd.
• 10. GlaxoSmithKline PLC
• 11. Globe Quimica S.A.
• 12. Granules India Limited
• 13. Hebei Jiheng (Group) Pharmaceutical Co., Ltd.
• 14. Hubei Biocause Heilen Pharmaceutical Co., Ltd.
• 15. Jiangsu Nanjing Huaxing Chemical Co., Ltd.
• 16. Jiangsu Pioneer Pharma Co., Ltd.
• 17. Lupin Pharmaceuticals, Inc.
• 18. Merck & Co., Inc.
• 19. Mylan N.V.
• 20. Nanjing Well Pharmaceutical Technology Co., Ltd.
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. SEQENS SAS
• 24. Shandong Xinhua Pharmaceutical Co., Ltd.
• 25. Sun Pharmaceutical Industries Ltd.
• 26. Taj Pharmaceuticals Ltd.
• 27. Zhenjiang Gaopeng Pharmaceutical Co., Ltd.